Eleisons mission is to acquire, develop, and

commercialize clinical stage drug candidates for

orphan cancers, providing new hope for patients
with rare, life-threatening diseases.
ABOUT ELEISONS CLINICAL TRIALS
Clinical trials are an important and necessary component of the drug
development process, in order to evaluate the safety and efficacy of new drug
candidates. Eleison is currently conducting clinical trials of its two drug
candidates at leading hospitals and cancer treatment centers in the United
States and around the world. Read More
Eleison is currently developing ILC, a breakthrough
therapeutic for the treatment of patients with a
rare form of bone cancer known as osteosarcoma .
INHALED LIPID-COMPLEXED CISPLATIN - ILC
Engineered specifically for nebulized lung delivery.
Patented lipid formulation of cisplatin in ~0.4 m particles deliver sustained
drug release in the lung.
Concentrations in lung at least 10x higher and systemic toxicities much lower
than intravenous dosing of cisplatin.
Safety data showed no hematologic toxicity, nephrotoxicity, ototoxicity, or
neurotoxicity.

ILC has been tested in dozens of patients in several clinical trials.
ILC clinical trial activity:
ILC has been tested in patients with NSCLC (non-small cell lung cancer),
bronchoalveolar cancer, and osteosarcoma.
ILC is currently being evaluated in a phase II clinical trial, to test the safety and
efficacy of ILC in patients with osteosarcoma which has spread to the lungs.
Participating hospitals in the ongoing clinical trial for osteosarcoma include
Memorial Sloan-Kettering, Montefiore Childrens Hospital, Moffitt Cancer
Center, University of Chicago Childrens Hospital, Childrens Hospital of Los
Angeles, University of Utah Primary Childrens Hospital, Washington University
(St. Louis), and others soon to be added. See www.clinicaltrials.gov for more
information about Eleisons clinical trial of ILC.

Osteosarcoma is a rare and often fatal bone cancer.
About Osteosarcoma:
Osteosarcoma is primarily a disease of teenagers and young adults.
500 new cases annually in US, 800 new cases annually in Europe.
Upon diagnosis, patients are treated with surgery and systemic combination
chemotherapy.
30% to 35% of patients fail first-line therapy, most commonly with
metastatic recurrence only in the lungs, with poor prognosis (five year
survival of such patients is < 25%)
No drugs are currently approved in the U.S. to treat osteosarcoma patients
who have failed first-line therapy.

For More Information:
Eleison Pharmaceuticals, LLC

263 13
th
Avenue South, Suite 375
St. Petersburg, FL 33701

ph: 215-554-3530
info@eleison-pharma.com